The vaccine against SARS-CoV-2 developed by Pfizer Inc. and BioNTech SE could become available for high-risk populations toward the end of this year if the companies are able to secure an emergency use authorization from the US Food and Drug Administration.
Coronavirus Update: Pfizer, BioNTech Hit Ground Running On Vaccine EUA
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
More from COVID-19
More from Scrip
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.